Proteins and Peptides
Proteins and peptidesAccessory Reagents & Controls
Accessory reagents & controlsBiochemicals
BiochemicalsFeatured product
Step up your high-throughput screening with our 384-well SimpleStep ELISA kits.
Learn more about all our product ranges with our product overviews.
Featured events
Make new connections at our global events.
Our programs
New Lab Program
Get a head start with our exclusive new lab discount. Enjoy 20% off and free shipping for three months.
New Biotech Program
Just starting out? Get 15% off and free shipping to your lab for six months.
Product promise
Peace of mind that all products perform as stated.
Product reviews
Leave reviews, get rewarded and help your community.
Trial program
Try untested species and applications to earn money off your next order.
This pathway, created in collaboration with Jeroen Middelbeek, reviews the different steps of tumor formation and metastasis, from EMT to angiogenesis. We outline key factors influencing this process
Show moreCell metastasis – an overview
Metastasis is a complex, multi-step process in which cells originating from a primary tumor spread throughout a patient's body to form secondary tumors in distant organs. Metastatic tumors cause more than 90% of cancer deaths1 and often require multiple rounds of treatment, including chemotherapy, targeted therapy, and immunotherapy to induce remission.
A secondary tumor results from cells acquiring the ability to circumvent the molecular and physical hurdles they encounter during each stage of the metastatic process. Only a few metastasized cells overcome these hurdles - most succumb to the various stresses they face during the process2.
Interactions between cancer cells, stromal fibroblasts, endothelial cells, and immune cells, and changes in tissue oxygen tension and the architecture of the extracellular matrix architecture greatly influence metastasis and, therefore, tumor progression.
The key stages in the metastatic process are proliferation, invasion, intravasation, capture by cell adhesion, extravasation, capture by physical occlusion, and, finally, secondary tumor growth.
Epithelial-to-mesenchymal transition
During the epithelial-to-mesenchymal transition (EMT), epithelial cells undergo multiple changes to acquire the properties of mesenchymal cells. These mesenchymal-like cancer cells migrate and invade tissues. Normal epithelial cell tissue architecture is maintained by contact inhibition. Cancer cells overcome contact inhibition via dysregulation of cell adhesion signaling and upregulation of master regulators of EMT, such as ZEB13.
YAP/TAZ are sensors and mediators of mechanical cues instructed by the cellular microenvironment4. The rigidity of the surrounding tumor matrix may influence tumor progression. Stiffer matrices could promote nuclear localization and activation of mechanomediators, such as TWIST1 and YAP/TAZ, leading to cytoskeleton remodeling during EMT5.
When a cell has completed the EMT process, it releases gelatinase enzymes, such as MMP-2 and MMP-9, to degrade the underlying basement membrane and allow the mesenchymal cell to migrate away from the epithelial layer in which it originated6.
Invasion
Cancer cells can migrate individually or as a collective group. Actin and myosin contractions in mesenchymal-like cancer cells lead to changes in cell shape, facilitating invasion through the extracellular matrix (ECM). Substrate binding integrins generate traction force in cells at the leading edge to mediate cell movement. There is a degradation of the ECM so that the cell can move forwards via protrusion into the space created. At the trailing edge, adhesion ceases, and the "tail" of the cell is retracted.
Intravasation and cell adhesion
Intravasation is the invasion of cancer cells through the basement membrane into the blood or lymphatic vessels. An inflammatory response introduces vascular permeability during intravasation by affecting endothelial cell-cell adhesions.
Cancer cells roll through the vascular space propelled by a series of weak adhesive interactions between selectins expressed on the surface of endothelial cells and CD44, CEA, and PODXL on the surface of tumor cells7. This rolling continues until the endothelium releases soluble adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM1) and intercellular adhesion molecule-1 (ICAM1). These molecules arrest cells through an interaction with integrin-mediated cell-matrix adhesions followed by neutrophil aggregation8,9.
Extravasation
The next stage is extravasation, where tumor cells induce vessel remodeling to permit invasion via integrin-mediated adhesion or TWIST1-mediated migration10. Common sites of metastasis include the lungs, lymph nodes, bones, liver, and brain. The microenvironment of the new site must be permissive to allow the tumor cell to survive and proliferate11.
Angiogenesis
As a tumor expands, the existing vascular supply is insufficient to provide enough oxygen, resulting in hypoxia. To continue expansion, a tumor requires new blood vessels to provide rapidly proliferating tumor cells with an adequate supply of oxygen and metabolites. Secondary tumors produce growth factors, such as vascular endothelial growth factors (VEGFs), to promote the formation of new blood vessels from surrounding tissues via angiogenesis12.
The poster provides an overview of metastasis from EMT to angiogenesis. We outline several critical factors influencing this process and highlight how the tumor cell environment may promote metastasis.